Poolbeg Pharma (POLB) Share Price, News & Analysis

Company Overview

Poolbeg Pharma plc is focussed on the development and commercialisation of innovative medicines targeting serious diseases with a high unmet medical need. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt’s success and generating near term revenues. Poolbeg’s clinical programmes target large addressable markets including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality data to support partnering and further development. Its AI-led discovery programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.

Key Stats

• Today's Range: 3.86 to 4.10
• 50-Day Range: 3.90 to 7.60
• 52-Week Range: 3.55 to 15.77
• Volume: 8.22 million shs
• Average Volume: 3.60 million shs
• Market Capitalization: £20.30 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

POLB Stock Analysis - Frequently Asked Questions

How have POLB shares performed this year?

Poolbeg Pharma's stock was trading at GBX 7.10 at the beginning of 2025. Since then, POLB stock has decreased by 44.4% and is now trading at GBX 3.95.
View the best growth stocks for 2025 here.

How do I buy shares of Poolbeg Pharma?

Shares of POLB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Poolbeg Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Poolbeg Pharma investors own include EQTEC (EQT), Great Western Mining (GWMO), Power Metal Resources (POW), Premier African Minerals (PREM), Rolls-Royce Holdings plc (RR), Alzamend Neuro (ALZN) and Alpine 4 (ALPP).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:POLB
• CUSIP: N/A
• CIK: N/A
• Web: www.poolbegpharma.com
• Phone: 44 20 7183 1499
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (851.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-4,500,219,166.67
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -32.56%
• Return on Assets: -21.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 19.61
• Quick Ratio: 47.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 1.88 per share
• Price / Cash Flow: 2.11
• Book Value: GBX 2,489.80 per share
• Price / Book: 0.00

Miscellaneous

• Outstanding Shares: 513,958,333
• Free Float: N/A
• Market Cap: £20.30 million
• Optionable: Not Optionable
• Beta: 2.11